We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2013 by Iwona Stelmach, Medical Universtity of Lodz.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00496574
First Posted: July 4, 2007
Last Update Posted: February 7, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Iwona Stelmach, Medical Universtity of Lodz
  Purpose
The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of SIT in children with asthma.

Condition Intervention Phase
Asthma Biological: Novo Helisen Depot, Phostal Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Long-term Clinical Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma

Further study details as provided by Iwona Stelmach, Medical Universtity of Lodz:

Primary Outcome Measures:
  • clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function [ Time Frame: baseline (first visit), 12 months (second visit), 24 months (third visit), 36 months (fourth visit) ]

Secondary Outcome Measures:
  • bronchial hyperreactivity with methacholine, and presence and type of allergy after tree years of SIT in children with asthma. [ Time Frame: after 36 months (fourth visit) ]

Estimated Enrollment: 60
Study Start Date: May 2006
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Biological: Novo Helisen Depot, Phostal
subcutaneous immunotherapy
Other Name: Novo Helisen Depot
No Intervention: 2
no intevention

Detailed Description:

According to Global Initiative for Asthma treatment of asthma is based on avoidance of allergens, pharmacological treatment, and specific immunotherapy.

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of SIT in children with asthma.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   8 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients allergic to house dust mites
  • patients with moderate bronchial asthma
  • patients with controlled asthma
  • patients who were qualified for immunotherapy and gave written informed consent for immunotherapy (active treatment group)
  • patients who were qualified for immunotherapy and did not agree with this kind of treatment - did not give written informed consent for immunotherapy (control group)

Exclusion Criteria:

  • patients allergic for other perennial and seasonal allergens
  • patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator
  • medications that resulted in patient exclusion included:anti-parasites or oral corticosteroids within 6 months before the first visit.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00496574


Contacts
Contact: Agnieszka Sobocińska, MD 00 48 42 6895972 alergol@kopernik.lodz.pl

Locations
Poland
Department of Pediatrics and Allergy, Medical University of Lodz, Poland Recruiting
Lodz, Poland, 93-513
Contact: Agnieszka Sobocińska, MD    00 48 42 6895972    alergol@kopernik.lodz.pl   
Principal Investigator: Iwona Stelmach, MD PhD Prof         
Sub-Investigator: Agnieszka Sobocińska, MD         
Sponsors and Collaborators
Medical Universtity of Lodz
Investigators
Principal Investigator: Agnieszka Sobocińska, MD Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland
Study Chair: Iwona Stelmach, MD PhD Prof Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland
  More Information

Responsible Party: Iwona Stelmach, MD, PhD, Professor, Medical Universtity of Lodz
ClinicalTrials.gov Identifier: NCT00496574     History of Changes
Other Study ID Numbers: RNN-102-06-KE
First Submitted: July 3, 2007
First Posted: July 4, 2007
Last Update Posted: February 7, 2013
Last Verified: February 2013

Keywords provided by Iwona Stelmach, Medical Universtity of Lodz:
asthma
immunotherapy
efficacy
children
symptoms score
quality of life
spirometry
PC20M

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases